Curriculum-Based Online and Live Activities


Course Director
Ian W. Flinn, MD, PhD
Sarah Cannon Research Institute
Nashville, Tennessee

Curriculum Description

In recent years, the rapid emergence of several classes of novel therapy and next-generation antibodies, such as B-cell receptor (BCR) inhibitors, immunomodulators, Bcl-2 inhibitors, and new anti-CD20 antibodies, has begun to change the management landscape of B-cell malignancies, including both indolent and aggressive non-Hodgkin lymphoma (NHL). Currently, these innovative therapies are being investigated in different disease settings, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL), among others, where they may add more potent options to the existing arsenal of active therapies, or where conventional options have not been associated with clinical benefits.

Through this curriculum, we hope to provide hematology-oncology professionals with the necessary knowledge and skill to safely integrate validated and more effective treatment options into NHL patient care and personalize treatment regimens based on relevant patient- and disease-related features. To learn more, join Dr. Ian Flinn for this engaging two-part educational activity, and then register to have one of our experts join you on-site for an interactive discussion.

Target Audience

This activity will directly target hematologists, hematologist-oncologists, medical oncologists, and advanced practice nurses who are presently active in patient care.